Skip to main content

Table 3 change assessment at each group

From: Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis

Group Mean Std. Deviation Paired t P
Group1 FVC (ml) 1287.6000 106.79760 − 0.990 0.3125
FVC (ml) 6M 1265.5530 215.15587   
FVC%predicted 55.7500 4.26584 0.340 0.814
FVC%predicted 6M 53.8500 6.42589   
6MWT (m) 287.5000 33.06692 1.785 0.0674
6MWT (m) 6M 310.0000 74.09809   
PaO2 at rest 64.7500 2.31414 − 1.653 0.0881
PaO2 at rest 6M 66.0500 2.81864   
SaO2 93.5000 2.48151 1.245 0.124
SaO2 6M 94.1500 3.52846   
PAP 35.0000 7.36278 1.085 0.231
PAP 6M 33.0000 6.56947   
SGRQ SCORE 37.2000 1.43637 1.106 0.224
SGRQ SCORE 6M 38.2500 2.35123   
Group2 FVC (ml) 1276.0000 106.74120 4.745 0.00**
FVC (ml) 6M 1100.5000 109.46160   
FVC%predicted 57.4500 6.16542 1.879 0.052
FVC%predicted 6M 48.5000 4.53640   
6MWT 290.0000 28.83711 4.314 0.00**
6MWT 6M 267.0000 37.98892   
PaO2 at rest 62.8500 4.24605 3.088 0.002*
PaO2 at rest 6M 54.9000 3.53777   
SaO2 92.5000 2.65370 − 5.139 0.00**
SaO2 6M 87.0000 3.07794   
PAP 33.2500 5.74800 − 2.019 0.048*
PAP 6M 36.8000 5.95686   
SGRQ SCORE 37.8500 2.42441 − 3.795 0.00**
SGRQ SCORE 6M 44.5000 2.35627   
  1. *refer to significant results
  2. **refer to highly significant results
  3. FVC forced vital capacity, 6MWT 6 minutes walking test, PaO2 partial pressure of oxygen in arterial blood, SaO2 oxygen saturation in arterial blood, PAP pulmonary artery pressure, SGRQ St. George’s Respiratory Questionnaire